PortfoliosLab logo
Nemaura Medical Inc. (NMRD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US6404422080

CUSIP

640442208

IPO Date

Mar 4, 2016

Highlights

Market Cap

$4.04K

EPS (TTM)

-$0.39

Year Range

$0.00 - $0.06

Target Price

$1.50

Short %

0.31%

Short Ratio

0.30

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Nemaura Medical Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Nemaura Medical Inc. (NMRD) returned 0.00% year-to-date (YTD) and -99.78% over the past 12 months.


NMRD

YTD

0.00%

1M

0.00%

6M

-50.00%

1Y

-99.78%

3Y*

-96.69%

5Y*

-89.35%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of NMRD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20250.00%0.00%100.00%-50.00%0.00%0.00%
2024-57.53%-18.28%17.11%-32.58%-20.00%21.67%-45.21%-3.12%-19.35%-99.20%0.00%-50.00%-99.95%
2023-22.54%-25.86%-9.23%-17.32%-32.58%85.43%-2.15%-49.18%-31.52%-17.14%-15.33%-0.90%-87.25%
2022-11.78%-6.04%15.61%-17.16%-23.48%-7.22%-25.68%-0.52%9.47%16.35%-9.92%-21.23%-62.34%
202112.73%46.12%23.03%-37.17%183.54%-23.95%-26.76%-7.78%-14.02%5.66%-23.62%-5.98%20.95%
2020-9.14%71.38%7.52%-15.02%46.59%26.71%-31.46%-41.01%-5.08%0.00%15.49%-8.05%7.71%
201916.67%10.90%-11.54%-6.78%-6.27%11.11%-16.59%-6.49%-6.41%2.23%-23.62%-38.60%-61.11%
201810.39%-8.53%-11.65%-27.47%-15.15%-0.00%-17.50%-9.74%14.15%-18.07%-2.56%-52.63%-82.35%
2017-6.67%78.57%20.00%140.00%-24.31%19.27%-17.93%-14.05%3.60%5.26%2.00%240.00%
2016-14.29%-16.67%0.00%30.00%-2.56%-4.74%-17.13%0.00%-28.57%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NMRD is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of NMRD is 2323
Overall Rank
The Sharpe Ratio Rank of NMRD is 3030
Sharpe Ratio Rank
The Sortino Ratio Rank of NMRD is 3434
Sortino Ratio Rank
The Omega Ratio Rank of NMRD is 3333
Omega Ratio Rank
The Calmar Ratio Rank of NMRD is 00
Calmar Ratio Rank
The Martin Ratio Rank of NMRD is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Nemaura Medical Inc. (NMRD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Nemaura Medical Inc. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.35
  • 5-Year: -0.51
  • All Time: -0.49

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Nemaura Medical Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Nemaura Medical Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Nemaura Medical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Nemaura Medical Inc. was 100.00%, occurring on Oct 17, 2024. The portfolio has not yet recovered.

The current Nemaura Medical Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%May 16, 20171861Oct 17, 2024
-33.33%Mar 17, 201617Feb 16, 20173Mar 24, 201720
-33.33%Apr 17, 20171Apr 17, 20173Apr 20, 20174
-28.99%Apr 26, 20172Apr 27, 20177May 8, 20179
-5.6%Apr 10, 20171Apr 10, 20171Apr 11, 20172
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Nemaura Medical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Nemaura Medical Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 100.0% positive surprise.


-0.15-0.10-0.050.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober20240
-0.10
Actual
Estimate

Valuation

The Valuation section provides an overview of how Nemaura Medical Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for NMRD compared to other companies in the Medical Devices industry. NMRD currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for NMRD relative to other companies in the Medical Devices industry. Currently, NMRD has a P/S ratio of 766.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for NMRD in comparison with other companies in the Medical Devices industry. Currently, NMRD has a P/B value of 122.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items